People | February 09, 2022
Strand Therapeutics appoints Dr. Prashant Nambiar as Senior VP
Senior R&D leader from Pfizer and bluebird bio to support Strand’s platform of programmable mRNA-based therapeutics
Senior R&D leader from Pfizer and bluebird bio to support Strand’s platform of programmable mRNA-based therapeutics
KEYTRUDA is now approved as monotherapy for adults with Renal Cell Carcinoma (RCC)
Optimized for pharma/biopharma to deliver a deeper understanding of cellular function
It is the first CAR T Therapy approved for the treatment of multiple myeloma in Japan
Upon completion of successful human trials and regulatory approval, the joint venture's goal is to start delivering the second-generation vaccine in 2022 as soon as is practically possible
The NMPA approval is based on the positive data of GEMSTONE-302 study, a multi-center, randomized, double-blind, phase III study that evaluated the efficacy and safety of Cejemly or placebo in combination with chemotherapy in first-line stage IV NSCLC patients
The medicine is the first and only oral MET inhibitor to receive CHMP positive opinion in Europe for adult patients with advanced NSCLC harbouring alterations leading to METex14 skipping
The company will manufacture a cancer immunotherapy product from 2022
This further adds to Biocon’s portfolio of vertically integrated complex drug products
The multi-target agreement covers five programmes focused on off-the-shelf vaccines for cancer and infectious disease
Subscribe To Our Newsletter & Stay Updated
